The FDA has approved two revolutionary cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease for patients 12 years of age and older, marking a significant step forward in the treatment of the disease.
AARP DC (sponsored Content)
We proudly serve the African-American communities in the DMV. Learn more about how we serve you.
The Washington Informer
2023 Financial Literacy Supplement
MORE TOP STORIES
Make A Donation
The Washington Informer remains a watchdog for D.C. residents. Readers like you make our reporting possible. Will you donate and become a member?
Subscribe to the Newsletter
The Washington Informer remains a watchdog for D.C. residents. Subscribe to The Daily for the latest news, delivered in a convenient, easy to read format.